Ocugen OCGN is advancing three one-time gene therapy programs for retinal diseases, each aimed at conditions with large unmet ...

A 24-year-old man developed progressive bilateral visual decline (left worse than right) after >1 year of non-medical oral exposure to a suspected tiletamine-containing product obtained online. He ...

It's well known that spaceflight causes muscle atrophy and other biological changes in reduced gravity, and especially in near-zero gravity (microgravity) environments. However, the gravity threshold ...

As we cross the threshold into an era defined by nonstop dialogue with Large Language Models (LLMs), a haunting existential question emerges: Is our capacity for genuine human connection beginning to ...

SAN CARLOS, Calif.--(BUSINESS WIRE)--Diffuse Bio, a leading provider of AI and experimental platforms for designing and screening protein therapeutics, today announced significant enhancements to ...

A novel outcome measure for geographic atrophy, the Geographic Atrophy Weighted-by-Acuity Index, aligned with best-corrected visual acuity, showing better correlation and predictive accuracy than the ...

While there is currently no cure for geographic atrophy, certain treatments, such as complement inhibitors, can help slow its progression by targeting immune system activity that damages the macula.

Geographic atrophy (GA) is a condition that typically progresses slowly, with lesions expanding by about 1 square millimeter per year, leading to blind spots due to retinal deterioration. Treatment ...

As previously noted, the most distinct characteristic of geographic atrophy (GA) are atrophic lesions in the retina. To assess the rate of GA progression, the area that the lesions occupy is measured ...

Novartis secured approval for its drug to treat certain patients diagnosed with spinal muscular atrophy from the Food and Drug Administration. Itvisma, or onasemnogene abeparvovec-brve, was approved ...

In boardrooms and executive offices, digital transformation is a catchphrase, but it is now met with more frustration than optimism. Yet, a recent Capgemini report paints a grimmer picture: 73% of ...

Many leaders tout the promise of AI, but also worry that workers will lose the ability to do certain tasks. A new Wharton School survey found that 43% of leaders have fears of skill atrophy due to AI.